drugdev limited
drugdev limited Company Information
Company Number
06026452
Website
www.drugdev.comRegistered Address
3 forbury place, 23 forbury road, reading, RG1 3JH
Industry
Other human health activities
Telephone
02030755000
Next Accounts Due
September 2025
Group Structure
View All
Directors
Imran Mecci5 Years
Shareholders
iqvia ltd 100%
drugdev limited Estimated Valuation
Pomanda estimates the enterprise value of DRUGDEV LIMITED at £0 based on a Turnover of £0 and 0.47x industry multiple (adjusted for size and gross margin).
drugdev limited Estimated Valuation
Pomanda estimates the enterprise value of DRUGDEV LIMITED at £0 based on an EBITDA of £0 and a 4.3x industry multiple (adjusted for size and gross margin).
drugdev limited Estimated Valuation
Pomanda estimates the enterprise value of DRUGDEV LIMITED at £36.4m based on Net Assets of £15.7m and 2.32x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Drugdev Limited Overview
Drugdev Limited is a live company located in reading, RG1 3JH with a Companies House number of 06026452. It operates in the other human health activities sector, SIC Code 86900. Founded in December 2006, it's largest shareholder is iqvia ltd with a 100% stake. Drugdev Limited is a established, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Drugdev Limited Health Check
There is insufficient data available to calculate a health check for Drugdev Limited. Company Health Check FAQs
0 Strong
0 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Drugdev Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Drugdev Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Drugdev Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Drugdev Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (18)
- Drugdev Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Drugdev Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Drugdev Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Drugdev Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Drugdev Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Drugdev Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Drugdev Limited
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Drugdev Limited
- - Industry AVG
DRUGDEV LIMITED financials
Drugdev Limited's latest turnover from December 2023 is 0 and the company has net assets of £15.7 million. According to their latest financial statements, we estimate that Drugdev Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 0 | 0 | 0 | 0 | 3,041,322 | 3,938,357 | 3,868,563 | 2,250,964 | 1,657,405 | 2,067,343 | 1,311,254 | 448,999 | |||
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Cost Of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Gross Profit | 0 | 0 | 0 | 0 | 3,041,322 | 3,938,357 | 3,868,563 | 2,250,964 | 1,657,405 | 2,067,343 | |||||
| Admin Expenses | 0 | 0 | 0 | 0 | 4,003,897 | 4,968,453 | 4,428,881 | 3,924,063 | 3,229,674 | 3,140,383 | |||||
| Operating Profit | 0 | 0 | 0 | 0 | -962,575 | -1,030,096 | -560,318 | -1,673,099 | -1,572,269 | -1,073,040 | -1,083,827 | 1,219 | |||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 295 | 1,121 | |||
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | |||
| Pre-Tax Profit | 0 | 0 | 0 | 0 | 11,572,446 | -1,030,096 | -560,318 | -1,673,093 | -1,572,269 | -1,073,040 | -1,083,827 | 174 | |||
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 101,972 | 0 | 228 | 0 | 200 | |||
| Profit After Tax | 0 | 0 | 0 | 0 | 11,572,446 | -1,030,096 | -560,318 | -1,571,121 | -1,572,269 | -1,072,812 | -1,083,827 | 374 | |||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Retained Profit | 0 | 0 | 0 | 0 | 11,572,446 | -1,030,096 | -560,318 | -1,571,121 | -1,572,269 | -1,072,812 | -1,083,827 | 374 | |||
| Employee Costs | 0 | 0 | 0 | 0 | 2,926,245 | 3,403,800 | 2,942,241 | 3,010,785 | 2,010,980 | 1,777,351 | 1,470,272 | 369,192 | |||
| Number Of Employees | 46 | 51 | 50 | 42 | |||||||||||
| EBITDA* | 0 | 0 | 0 | 0 | -953,906 | -1,005,921 | -509,356 | -1,621,897 | -1,525,179 | -1,030,451 | -1,063,496 | 2,844 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 39,516 | 62,279 | 113,241 | 164,443 | 171,496 | 190,499 | 3,842 | 2,140 | 719 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 112,398 | 112,398 | 112,398 | 112,398 | 112,398 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 39,516 | 174,677 | 225,639 | 276,841 | 283,894 | 302,897 | 3,842 | 2,140 | 719 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12,395 | 909 | 5,052 |
| Group Debtors | 15,682,521 | 15,682,521 | 15,682,521 | 15,682,521 | 15,682,521 | 2,784,265 | 2,182,490 | 769,431 | 125,467 | 47,922 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 333,025 | 378,587 | 327,934 | 160,805 | 114,547 | 102,689 | 7,516 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 245,699 | 141,270 | 254,483 | 31,738 | 329,470 | 119,059 | 118,209 | 797 | 10,481 | 273 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 15,682,521 | 15,682,521 | 15,682,521 | 15,682,521 | 15,682,521 | 3,362,989 | 2,702,347 | 1,351,848 | 318,010 | 491,939 | 221,748 | 125,725 | 13,192 | 11,390 | 5,325 |
| total assets | 15,682,521 | 15,682,521 | 15,682,521 | 15,682,521 | 15,682,521 | 3,402,505 | 2,877,024 | 1,577,487 | 594,851 | 775,833 | 524,645 | 129,567 | 15,332 | 12,109 | 5,325 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 19,086 | 79,423 | 80,400 | 44,712 | 48,176 | 86,934 | 28,799 | 14,760 | 11,832 | 5,202 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 9,657,389 | 8,194,950 | 6,519,520 | 4,141,270 | 2,719,238 | 1,090,191 | 57,542 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 615,955 | 462,480 | 277,078 | 137,259 | 164,540 | 430,601 | 42,480 | 0 | 0 | 0 |
| total current liabilities | 0 | 0 | 0 | 0 | 0 | 10,292,430 | 8,736,853 | 6,876,998 | 4,323,241 | 2,931,954 | 1,607,726 | 128,821 | 14,760 | 11,832 | 5,202 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 228 | 228 | 428 | 144 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 228 | 228 | 428 | 144 | 0 |
| total liabilities | 0 | 0 | 0 | 0 | 0 | 10,292,430 | 8,736,853 | 6,876,998 | 4,323,241 | 2,931,954 | 1,607,954 | 129,049 | 15,188 | 11,976 | 5,202 |
| net assets | 15,682,521 | 15,682,521 | 15,682,521 | 15,682,521 | 15,682,521 | -6,889,925 | -5,859,829 | -5,299,511 | -3,728,390 | -2,156,121 | -1,083,309 | 518 | 144 | 133 | 123 |
| total shareholders funds | 15,682,521 | 15,682,521 | 15,682,521 | 15,682,521 | 15,682,521 | -6,889,925 | -5,859,829 | -5,299,511 | -3,728,390 | -2,156,121 | -1,083,309 | 518 | 144 | 133 | 123 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 0 | 0 | 0 | 0 | -962,575 | -1,030,096 | -560,318 | -1,673,099 | -1,572,269 | -1,073,040 | -1,083,827 | 1,219 | |||
| Depreciation | 0 | 0 | 0 | 0 | 8,669 | 24,175 | 50,962 | 51,202 | 47,090 | 42,589 | 20,331 | 1,625 | 793 | 240 | 0 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 101,972 | 0 | 228 | 0 | 200 | |||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 0 | 0 | 0 | 0 | 12,565,231 | 443,815 | 1,463,712 | 811,093 | 123,803 | 59,780 | 207,571 | -4,879 | 11,486 | -4,143 | 5,052 |
| Creditors | 0 | 0 | 0 | 0 | -19,086 | -60,337 | -977 | 35,688 | -3,464 | -38,758 | 58,135 | 14,039 | 2,928 | 6,630 | 5,202 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | -615,955 | 153,475 | 185,402 | 139,819 | -27,281 | -266,061 | 388,121 | 42,480 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -228 | 0 | -200 | 284 | 144 | 0 |
| Cash flow from operations | 0 | 0 | 0 | 0 | -14,154,178 | -1,356,598 | -1,788,643 | -2,155,511 | -1,679,727 | -1,395,050 | -824,811 | 64,242 | |||
| Investing Activities | |||||||||||||||
| capital expenditure | 0 | 0 | -40,037 | -23,958 | |||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | 0 | 0 | -40,037 | -23,958 | |||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | -9,657,389 | 1,462,439 | 1,675,430 | 2,378,250 | 1,422,032 | 1,629,047 | 1,032,649 | 57,542 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | -295 | -1,121 | |||
| cash flow from financing | 0 | 0 | 0 | 0 | 1,342,611 | 1,462,439 | 1,675,430 | 2,378,256 | 1,422,032 | 1,629,047 | 1,032,354 | 56,421 | |||
| cash and cash equivalents | |||||||||||||||
| cash | 0 | 0 | 0 | 0 | -245,699 | 104,429 | -113,213 | 222,745 | -297,732 | 210,411 | 850 | 117,412 | -9,684 | 10,208 | 273 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | -245,699 | 104,429 | -113,213 | 222,745 | -297,732 | 210,411 | 850 | 117,412 | -9,684 | 10,208 | 273 |
drugdev limited Credit Report and Business Information
Drugdev Limited Competitor Analysis
Perform a competitor analysis for drugdev limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
drugdev limited Ownership
DRUGDEV LIMITED group structure
Drugdev Limited has no subsidiary companies.
Ultimate parent company
IQVIA HOLDINGS INC
#0013898
2 parents
DRUGDEV LIMITED
06026452
drugdev limited directors
Drugdev Limited currently has 1 director, Mr Imran Mecci serving since May 2019.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Imran Mecci | England | 47 years | May 2019 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
0
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
15.7m
0%
total assets
15.7m
0%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
drugdev limited company details
company number
06026452
Type
Private limited with Share Capital
industry
86900 - Other human health activities
incorporation date
December 2006
age
18
accounts
Dormant
ultimate parent company
previous names
binto limited (May 2012)
incorporated
UK
address
3 forbury place, 23 forbury road, reading, RG1 3JH
last accounts submitted
December 2023
drugdev limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to drugdev limited.
drugdev limited Companies House Filings - See Documents
| date | description | view/download |
|---|
